Xvivo Perfusion Gross Profit vs. Debt To Equity

XVIPF Stock  USD 42.90  1.67  4.05%   
Considering Xvivo Perfusion's profitability and operating efficiency indicators, Xvivo Perfusion AB may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in December. Profitability indicators assess Xvivo Perfusion's ability to earn profits and add value for shareholders.
For Xvivo Perfusion profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Xvivo Perfusion to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Xvivo Perfusion AB utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Xvivo Perfusion's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Xvivo Perfusion AB over time as well as its relative position and ranking within its peers.
  
Check out Your Current Watchlist.
Please note, there is a significant difference between Xvivo Perfusion's value and its price as these two are different measures arrived at by different means. Investors typically determine if Xvivo Perfusion is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xvivo Perfusion's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Xvivo Perfusion AB Debt To Equity vs. Gross Profit Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Xvivo Perfusion's current stock value. Our valuation model uses many indicators to compare Xvivo Perfusion value to that of its competitors to determine the firm's financial worth.
Xvivo Perfusion AB is rated first in gross profit category among its peers. It is rated first in debt to equity category among its peers . The ratio of Gross Profit to Debt To Equity for Xvivo Perfusion AB is about  74,239,000,000 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Xvivo Perfusion's earnings, one of the primary drivers of an investment's value.

Xvivo Debt To Equity vs. Gross Profit

Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

Xvivo Perfusion

Gross Profit

 = 

Revenue

-

Cost of Revenue

 = 
296.96 M
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

Xvivo Perfusion

D/E

 = 

Total Debt

Total Equity

 = 
0 %
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.

Xvivo Debt To Equity Comparison

Xvivo Perfusion is currently under evaluation in debt to equity category among its peers.

Xvivo Perfusion Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Xvivo Perfusion, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Xvivo Perfusion will eventually generate negative long term returns. The profitability progress is the general direction of Xvivo Perfusion's change in net profit over the period of time. It can combine multiple indicators of Xvivo Perfusion, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Xvivo Perfusion AB , a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden. Xvivo Perfusion operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 115 people.

Xvivo Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Xvivo Perfusion. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Xvivo Perfusion position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Xvivo Perfusion's important profitability drivers and their relationship over time.

Use Xvivo Perfusion in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Xvivo Perfusion position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Xvivo Perfusion will appreciate offsetting losses from the drop in the long position's value.

Xvivo Perfusion Pair Trading

Xvivo Perfusion AB Pair Trading Analysis

The ability to find closely correlated positions to Xvivo Perfusion could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Xvivo Perfusion when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Xvivo Perfusion - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Xvivo Perfusion AB to buy it.
The correlation of Xvivo Perfusion is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Xvivo Perfusion moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Xvivo Perfusion AB moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Xvivo Perfusion can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Xvivo Perfusion position

In addition to having Xvivo Perfusion in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Utilities Thematic Idea Now

Utilities
Utilities Theme
Highly leveraged corporations that deliver utilities such as power, water or gas to public or business. The Utilities theme has 30 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Utilities Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Xvivo Pink Sheet

To fully project Xvivo Perfusion's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Xvivo Perfusion AB at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Xvivo Perfusion's income statement, its balance sheet, and the statement of cash flows.
Potential Xvivo Perfusion investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Xvivo Perfusion investors may work on each financial statement separately, they are all related. The changes in Xvivo Perfusion's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Xvivo Perfusion's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.